PFL-002 / Pierre Fabre - LARVOL DELTA

First-In-Human Phase I/II Trial of PFL-002/VERT-002 in Locally Advanced or Metastatic Solid Tumors Including NSCLC With MET Alterations (IASLC-WCLC 2025) - P1/2 | "Dose level 1 has been completed without DLT. Enrollment to dose level 2 began in December 2024."

First-in-human • Metastases • P1/2 data • CNS Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Psychiatry • Solid Tumor • MET

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241 (The Manila Times) - "Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ('Antares'), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs....'With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241'."

M&A • Non Small Cell Lung Cancer

FIH Trial of VERT-002 in Patients with Locally Advanced or Metastatic Solid Tumors with MET Alterations (clinicaltrials.gov) - P1/2 | N=140 | Recruiting | Sponsor: Pierre Fabre Medicament

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations (Canada Newswire) - "Pierre Fabre Laboratories announced today that the first patient has been dosed with PFL-002/VERT-002...in a phase I/II first-in-human dose-escalation, dose-optimization and dose-expansion trial, for patients with Non-Small Cell Lung Cancer (NSCLC) harbouring MET alterations."

Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations (PRNewswire) - "Pierre Fabre Laboratories today announced the filing of an investigational new drug ('IND') application to the U.S. Food and Drug Administration ('FDA') to initiate a first-in-human (FIH) Phase I/II clinical trial with PFL-002/VERT-002 for solid tumors including non-small cell lung cancer (NSCLC)...'We are looking forward to initiating the first-in-human trial of PFL-002/VERT-002 later this year.'...Pierre Fabre Laboratories is progressing PFL-002/VERT-002 into clinical development and hope to enroll a first patient in the FIH trial by end 2024."

IND • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration (Canada Newswire) - "Pierre Fabre Laboratories...announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of a biotechnology company allows Pierre Fabre Laboratories to add VERT-002 to its oncology discovery pipeline....VERT-002 is currently completing IND-enabling studies and Vertical Bio expects to begin first in human studies in 2024."

M&A • New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor